156 related articles for article (PubMed ID: 23083821)
1. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
Jenkins ET; Jensen DM
Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
3. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
4. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
5. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
[TBL] [Abstract][Full Text] [Related]
6. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
7. Treatment predictors of a sustained virologic response in hepatitis B and C.
Kau A; Vermehren J; Sarrazin C
J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C virus: the first decade.
Poynard T
Semin Liver Dis; 2004; 24 Suppl 2():19-24. PubMed ID: 15346242
[TBL] [Abstract][Full Text] [Related]
9. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S
J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050
[TBL] [Abstract][Full Text] [Related]
10. The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle?
Ralston R; Jacobson I; Scull M
Semin Liver Dis; 2011 Nov; 31(4):410-9. PubMed ID: 22189980
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus infection in end stage renal disease and after kidney transplant.
Rodriguez-Castro KI; Morisco F; Rigotti P; Rugge M; Burra P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):340-2. PubMed ID: 25267966
[No Abstract] [Full Text] [Related]
12. vRNA structured population model for Hepatitis C Virus dynamics.
Woot de Trixhe X; Krzyzanski W; De Ridder F; Vermeulen A
J Theor Biol; 2015 Aug; 378():1-11. PubMed ID: 25912382
[TBL] [Abstract][Full Text] [Related]
13. [Current management of hepatitis C].
Lange CM
Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851
[TBL] [Abstract][Full Text] [Related]
14. Complexities of HCV management in the new era of direct-acting antiviral agents.
Rosenberg WM; Tanwar S; Trembling P
QJM; 2014 Jan; 107(1):17-9. PubMed ID: 24065837
[TBL] [Abstract][Full Text] [Related]
15. Advances in and the future of treatments for hepatitis C.
Cheng R; Tu T; Shackel N; McCaughan GW
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):633-47. PubMed ID: 24846594
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection.
Grebely J; Matthews GV; Petoumenos K; Dore GJ
J Viral Hepat; 2010 Dec; 17(12):896. PubMed ID: 20051007
[No Abstract] [Full Text] [Related]
17. Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
Harrington PR; Deming DJ; Komatsu TE; Naeger LK
Clin Infect Dis; 2015 Aug; 61(4):666-7. PubMed ID: 26002846
[No Abstract] [Full Text] [Related]
18. Comparative hepatitis C genotype 1-3 viral load kinetics in response to directly-acting antiviral therapy.
May S; Kurmoo F; Iliffe M; David J; Patel A; Wiselka M; Stephenson I; Delahooke T; Lai FY; Dustan S; Tang JW
J Infect; 2020 May; 80(5):578-606. PubMed ID: 32017973
[No Abstract] [Full Text] [Related]
19. Significance of HCV RNA monitoring in the era of new potent therapies.
Wiesmann F; Braun P
Expert Rev Anti Infect Ther; 2016 Sep; 14(9):837-44. PubMed ID: 27424603
[TBL] [Abstract][Full Text] [Related]
20. Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies.
Del Campo JA; Romero-Gómez M
World J Gastroenterol; 2015 Oct; 21(38):10776-82. PubMed ID: 26478669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
